WVE-N531

WVE-N531 is an investigational antisense oligonucleotide designed to treat Duchenne muscular dystrophy (DMD) in patients amenable to exon 53 skipping. Developed by Wave Life Sciences, it utilizes proprietary stereopure chemistry with a phosphoryl guanidine (PN) backbone modification, which enhances tissue uptake and distribution, including in cardiac and respiratory muscles[1][5]. The drug works by inducing exon 53 skipping during pre-mRNA splicing of the dystrophin gene, enabling production of a truncated but functional dystrophin protein. This approach aims to convert out-of-frame mutations into in-frame deletions, resulting in milder DMD phenotypes[2][6]. Clinical trials have shown that WVE-N531 leads to sustained exon skipping, increased muscle concentrations of the drug, restoration of dystrophin expression (mean ~7–8% at 48 weeks), significant improvements in muscle health markers (reduced necrosis, inflammation, fibrosis), and functional benefits such as improved time-to-rise and hand grip strength[6][7][8]. The therapy has demonstrated safety and tolerability through at least 48 weeks of dosing. Wave Life Sciences plans to file for accelerated approval based on these results.